The Current Ratio as of November 2024 (TTM) for CSL Limited (CSLLY) is 2.18

According to CSL Limited’s latest financial reports and current stock price. The company's current Current Ratio is 2.18. This represents a change of 34.36% compared to the average of 1.62 of the last 4 quarters.

CSL Limited (CSLLY) Historical Current Ratio (quarterly & annually)

How has CSLLY Current Ratio performed in the past?

The mean historical Current Ratio of CSL Limited over the last ten years is 2.62. The current 2.18 Current Ratio has changed 8.20% with respect to the historical average. Over the past ten years (40 quarters), CSLLY's Current Ratio was at its highest in in the September 2021 quarter at 4.94. The Current Ratio was at its lowest in in the March 2024 quarter at 0.

CSL Limited (CSLLY) Current Ratio by Quarter and Year

Discovering the peaks and valleys of CSL Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

CSL Limited (CSLLY) Average Current Ratio

How has CSLLY Current Ratio performed in the past?

The current Current Ratio of CSL Limited (CSLLY) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

CSL Limited (CSLLY) Current Ratio vs. Peers

How is CSLLY’s Current Ratio compared to its peers?

CSL Limited’s Current Ratio is greater than Novo Nordisk A/S (0.94), greater than BeiGene, Ltd. (1.98), less than Acelyrin, Inc. (7.86), less than Caribou Biosciences, Inc. (8.75), less than Molecular Partners AG (14.58), less than Mineralys Therapeutics, Inc. (11.20), less than AN2 Therapeutics, Inc. (10.61), less than Pharvaris N.V. (18.45), less than PepGen Inc. (7.45), less than Ventyx Biosciences, Inc. (14.19), greater than CSL Limited (2.18), less than Bionomics Limited (3.45), less than Enzon Pharmaceuticals, Inc. (113.75), less than Cogent Biosciences, Inc. (9.25), less than Larimar Therapeutics, Inc. (13.10), less than Kura Oncology, Inc. (14.94), less than Kiniksa Pharmaceuticals, Ltd. (3.24), less than Cerevel Therapeutics Holdings, Inc. (10.22), less than Revolution Medicines, Inc. (15.42), less than Nuvalent, Inc. (17.44), less than RAPT Therapeutics, Inc. (8.14), less than Syndax Pharmaceuticals, Inc. (10.50), less than EQRx, Inc. (18.78),

Build a custom stock screener for CSL Limited (CSLLY) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like CSL Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

CSL Limited (CSLLY) and other stocks custom spreadsheet templates

The easiest way to analyze a company like CSL Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.